SAT0432 Correlation between the spinal MRI findings and new bone formation factor (DKK-1)i n patients with spondyloarthritis

Background Recent prospective data suggest that spinal inflammatory damage in patients with ankylosing spondylitis will eventually convert into fat. In these complex inflammatory lesions, bone formation and inflammation are not synchronized. The molecular basis responsible for new bone formation in SpA patients is still unclear. Serum level of dickkopf-1 (Dkk-1), the natural inhibitor of WNT protein, is a main factor in limiting new bone formation. Objectives In this study, we aimed to assess the correlation between the secreted protein Dkk-1 and abnormal findings on spinal MRI through a prospective study of SpA. Methods Thirty patients with active axial SpA (axSpA) who fulfilled the ASAS axSpA criteria were enrolled. All patients received an injection of recombinant human TNF receptor-antibody fusion protein (YISAIPU) at a dosage of 50 mg/week for 6 months. Patient report outcome measure questionnaires and physical examination, blood tests were completed according to the study protocol. All patients were scored for bone marrow edema and fat infiltration on spinal MRI imaging. The spinal MRI imaging of the patients before and after the treatment were blindly reviewed and scored using the SPARCC scoring system by two individuals who were familiar with the system. Results There are 28 male and two female patients (mean age: 31±5.5 yrs, range: 22–41; mean duration: 93.5±75.8; HLA-B27(+): 96.7% (29/30)). In patients who finished the 6 month anti-TNF treatment, the ESR, CRP, BASDAI, BASFI, BASMI and ASDAS-CRP were significantly decreased ( P P P 0.05). (Table1). Correlation analysis found that serum Dkk-1 concentration before treatment was significantly correlated with spinal bone marrow edema scores ( P P Conclusions Spinal marrow edema may have a role in predicting new bone formation in the spine, since the change of serum Dkk-1 level is correlated with change of spinal marrow edema. And Dkk-1 may participate in the molecular basis of the TNF inhibitor9s blockade of new bone formation. Further research is needed on patients who have received long-term TNF antagonist treatment to find the time points when serum Dkk-1 level reaches a stabilized plateau. Increased knowledge in this area will be helpful when assessing a predictive marker for the timing of treatment withdrawal. Disclosure of Interest None declared